Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients with Lymphoma
18 Years and older, Male and Female
This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.
I. To determine the seroprotection and seroconversion rates after influenza vaccination in patients with lymphoma receiving active treatment or in follow up observation.
I. To characterize influenza-specific plasmablasts and memory B cells after influenza vaccination in patients with lymphoma receiving active treatment or in follow up observation.
II. To investigate the longevity of humoral immunity to influenza virus in patients with lymphoma receiving active treatment or in follow up observation.
III. To assess the timing and strength of the peak immune response to influenza vaccination.
IV. To assess the effect of different lymphomas and treatment modalities in the immune response to influenza vaccination.
Patients receive seasonal inactivated influenza vaccine intramuscularly (IM) at day 0.
After completion of study treatment, patients are followed up at days 7, 14, 28, 90, and 180
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials